FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Adding Herceptin to chemotherapy in gastric cancer patients with ERBB2-positive tumors produced an 85% response rate.
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2 positive gastric... Read More
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Gastric cancer patients treated with Enhertu in a recent study had favorable response rates, survival and duration of response as compared to... Read More